Abstract:The acidosis anti-tumor therapy, based on the altered energy metabolism pathway of tumor cells, has been proposed as an attractive method for cancer selective treatment. However, the strategy of inducing tumor acidosis by using a single drug to simultaneously inhibit both lactate efflux and consumption has not been reported yet. Herein, an in situ enzyme-instructed self-assembly (EISA) system was rationally fabricated to induce tumor acidosis apoptosis for cancer selective therapy. Depending on the sequential effect of the in situ EISA system, the targeted drug was successively distributed on the membrane and intracellular, inhibiting MCT4 mediated lactate efflux and mitochondrial tricarboxylic acid (TCA) cycle mediated lactate consumption, respectively. Through the dual obstruction of lactate metabolism to trigger tumor acidosis, the in situ EISA nanomedicine showed selective growth and migration inhibition against cancer cells. In addition, the nanomedicine also displayed a radio-sensitization effect in vitro due to causing the mitochondrial dysfunction, and exhibited a prominent synergistic chemo-radiotherapy anti-tumor performance in vivo. Accordingly, this work demonstrated that the in situ EISA system could endow the LND with sequential-dual effects to induce tumor acidosis, which may provide an enlightening strategy for anticancer drug delivery and cancer selective therapy. STATEMENT OF SIGNIFICANCE: With the help of the sequential effect of in situ EISA , the serial attack of LND against different targets was effectively realized to induce tumor acidosis and combined chemo-radiotherapy, implying the importance of the relationship between structure and function, which could offer a distinctive inspiration for future drug delivery system design and anti-tumor application.

Integrating Enzymatic Self-Assembly and Mitochondria Targeting for Selectively Killing Cancer Cells without Acquired Drug Resistance

Cancer‐Selective Supramolecular Chemotherapy by Disassembly‐Assembly Approach

A Cascade-Targeted Enzyme-Instructed Peptide Self-Assembly Strategy for Cancer Immunotherapy through Boosting Immunogenic Cell Death

Self-modifying NanoEnhancers Facilitating Lysosomal Escape for Cgas-Sting Cascading Activation in Tumor Immunotherapy

Mitochondrial rewiring with small-molecule drug-free nanoassemblies unleashes anticancer immunity

A Mitochondria-Targeting Gold-Peptide Nanoassembly for Enhanced Cancer-Cell Killing

A Coupling‐Induced Assembly Strategy for Constructing Artificial Shell on Mitochondria in Living Cells

An enzyme-instructed self-assembly system induces tumor acidosis via sequential-dual effect for cancer selective therapy

Enzyme‐Instructed Supramolecular Self‐Assembly with Anticancer Activity

Rationally Designed Enzyme‐Resistant Peptidic Assemblies for Plasma Membrane Targeting in Cancer Treatment

Enzyme-instructed and mitochondria-targeting peptide self-assembly to efficiently induce immunogenic cell death

Hierarchical Nanoclusters with Programmed Disassembly for Mitochondria-Targeted Tumor Therapy with MR Imaging

Controlling Intracellular Enzymatic Self-Assembly of Peptide by Host-Guest Complexation for Programming Cancer Cell Death.

Lysosome-Mitochondria Cascade Targeting Nanoparticle Drives Robust Pyroptosis for Cancer Immunotherapy

Selective Degradation of PD‐L1 in Cancer Cells by Enzyme‐Instructed Self‐Assembly

Engineering biomimetic ATP-responsive Se-containing core-shell cascade nanozyme for efficient tumor combination therapy

Lysosome‐Targeted and Fluorescence‐Turned “On” Cytotoxicity Induced by Alkaline Phosphatase‐Triggered Self‐Assembly

A Ph-Responsive Sequential-Disassembly Nanohybrid for Mitochondrial Targeting

In Situ Supramolecular Self-assembly of Perylene Diimide Derivative in Mitochondria for Cancer Cell Ferroptosis

Rational design of self-assembled mitochondria- targeting lytic peptide conjugates with enhanced tumor selectivity.

Kinetic selectivity dictates the construction of cancer cell-targeting enzyme instructed supramolecular assemblies